<DOC>
	<DOCNO>NCT01959295</DOCNO>
	<brief_summary>To evaluate efficacy safety ASP2151 patient herpes simplex .</brief_summary>
	<brief_title>Phase III Study ASP2151 Herpes Simplex Patients</brief_title>
	<detailed_description>A double-blind , randomize , placebo-controlled , parallel-group study conduct evaluate efficacy safety ASP2151 patient herpes simplex ( labial/facial herpes recurrent genital herpes ) . The efficacy evaluate primary endpoint define , `` proportion subject achieve lesion heal Day 8 study treatment '' demonstrate superiority ASP2151 placebo . The safety evaluate base adverse event , laboratory test , vital sign , ECGs .</detailed_description>
	<mesh_term>Herpes Simplex</mesh_term>
	<criteria>1 . Patients rash associate moderate severe herpes simplex , oral antiviral medication indicate Labial/facial herpes : Patients least 10 papulae vesicles/pustules Recurrent genital herpes : Patients least 5 papulae vesicles/pustules genital organ genital circumanal region 2 . Patients start receive study drug within 48 hour onset rash 3 . Age : 20 year old , young 80 year 1 . Patients expect adequate response oral antiviral medication 2 . An extreme decline immune function 3 . Presence serious complication 4 . Patients find meet follow condition base laboratory test perform within 14 day inform consent : AST ALT ≥ 2.5 x upper limit normal Platelet count &lt; low limit normal Serum creatinine ≥ 1.5 mg/dL Creatinine clearance &lt; 30 mL/min 5 . Current previous history malignant tumor within 5 year inform consent 6 . Diagnosis autoimmune disease 7 . Evidence bone marrow suppression</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>